Proteros biostructures GmbH
Am Klopferspitz 19
Martinsried
D - 82152
Germany
Tel: 49-0-89-700761-0
Fax: 49-0-89-700761-15
Website: http://www.proteros.de/
Email: business@proteros.de
35 articles about Proteros biostructures GmbH
-
Proteros biostructures and Orion Pharma agree on a long-term multi-target collaboration including the assembly of a joint novel and unique HTS small-molecule screening library with the full chemistry support of Enamine
9/6/2023
Proteros biostructures GmbH announced a new collaboration with Orion Corporation.
-
Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases
10/25/2022
Adrestia Therapeutics announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH to accelerate the discovery of first-in-class candidate drugs for intractable diseases.
-
Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases
10/25/2022
Proteros biostructures GmbH announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases.
-
Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.
-
Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca
5/16/2022
Proteros biostructures GmbH, an expert in integrated structure-based drug discovery, announces an expansion of its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
6/2/2021
Proteros biostructures GmbH announced that it has signed an agreement with AstraZeneca to jointly discover and develop novel small molecules for the potential treatment of various types of cancer.
-
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
4/1/2021
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks
-
Proteros launches new cryo-EM facility to speed drug discovery
9/9/2020
Proteros will build a leading Center of Excellence for industrial cryo-EM applications to improve success rates in drug discovery
-
Proteros, co-founder of Rodin Therapeutics, announces Rodin’s acquisition by Alkermes
11/28/2019
Proteros biostructures GmbH announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland.
-
Proteros biostructures GmbH Names Dave Lemus as New Executive Board Member
12/6/2017
Previous to his appointment, Mr. Lemus was COO and CFO of Medigene AG, assisting in its transformation into an immunotherapy-based company through the establishment of strategic partnerships.
-
Proteros biostructures GmbH Forges $167 Million+ Cancer R&D Deal With Merck Sharp & Dohme
11/23/2016
-
Proteros biostructures GmbH Appoints Dr. Torsten Hoffmann As Chief Scientific Officer
6/29/2015
-
Proteros biostructures GmbH Enters Into A Collaboration With Bayer To Develop New Cardiovascular Drug Compounds For An Integral Membrane Protein
1/8/2015
-
Proteros biostructures GmbH: Proteros Announces Changes In Management Team
5/12/2014
-
Proteros biostructures GmbH and Eisai Company, Ltd. Achieve Target in Lead Discovery Project, Delivering Kinetically Optimized Lead Compounds
5/6/2013
-
Proteros biostructures GmbH and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets
4/9/2013
-
Nimbus Discovery and Proteros biostructures GmbH Enter into Privileged X-Ray Crystallography Partnership Agreement
11/8/2012
-
Proteros biostructures GmbH Announces Appointment of New Chief Financial Officer, Arnd Christ
10/11/2012
-
UCB, Inc. and Proteros biostructures GmbH Expand Successful Protein X-Ray Crystallography Collaboration
9/18/2012